ABCAM Plc Completion of Tender Offer (0421D)
January 23 2015 - 11:32AM
UK Regulatory
TIDMABC
RNS Number : 0421D
ABCAM Plc
23 January 2015
For immediate release 23 January 2015
ABCAM PLC
("Abcam" or "the Company")
Completion of Tender Offer re acquisition of Firefly BioWorks
Inc
Further to its announcement on 21 January 2015, Abcam plc (AIM:
ABC), a global leader in the supply of life science research tools,
today announces that it has it has completed the tender offer to
purchase all outstanding Firefly BioWorks Inc ("Firefly") shares
for cash [1].
The tender offer closed on 23 January 2015, at which time Abcam
had received valid acceptances from shareholders holding 100 per
cent. of Firefly's share capital.
[1] This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements.
For further information please contact:
+ 44 (0) 1223
Abcam 696 000
Alan Hirzel, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Laura Taylor - Investor Relations
J.P.Morgan Cazenove - Nominated Adviser & Joint + 44 (0) 20 7742
Corporate Broker 4000
James Mitford / Alex Bruce - Nominated Adviser
+ 44 (0) 20 7418
Peel Hunt LLP - Joint Corporate Broker 8900
Clare Terlouw / Jock Maxwell MacDonald - Corporate
Broking
+44 (0) 20 7404
Brunswick 5959
Justine Mcllroy / Will Medvei / Anna Carruth
Notes to Editors
About Firefly
Firefly offers a platform for solution-phase multiplexed
detection of proteins and nucleic acids. The company's open
platform allows industrial, academic, and clinical scientists to
develop and use multiplexed biological assays on standard
laboratory flow cytometers. Firefly was incorporated in 2009.
About Abcam
Abcam plc is a global leader in the supply of life science
research tools, with a wide range of products and expert technical
support, enabling scientists to analyse living cells at the
molecular level and improving the understanding of health and
disease.
Abcam is committed to providing scientists with an extensive
choice of reagents and tools, with the most comprehensive, honest
and up-to-date datasheets and customer reviews, fast delivery and
helpful customer service & technical support. The Company's
catalogue evolves with scientific research trends and is growing
each year to provide customers with products to meet their research
needs. The range now includes primary and secondary antibodies,
proteins, peptides, lysates, biochemicals, immunoassays and other
kits. Abcam also supports its customers by hosting a range of
global scientific events, forums and webinars, providing
opportunities for scientists to get together and present their
work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary
offices enabling local services and multi-language support and
sells to over 100 countries. The Company was founded in 1998, and
now employs over 750 people. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQQXLFLEFFXBBB
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024
